Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly DA Braun, J Rao, G Mollet, D Schapiro, MC Daugeron, W Tan, ... Nature genetics 49 (10), 1529-1538, 2017 | 192 | 2017 |
Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency S Lovric, S Goncalves, HY Gee, B Oskouian, H Srinivas, WI Choi, S Shril, ... The Journal of clinical investigation 127 (3), 912-928, 2017 | 188 | 2017 |
A kidney-disease gene panel allows a comprehensive genetic diagnosis of cystic and glomerular inherited kidney diseases G Bullich, A Domingo-Gallego, I Vargas, P Ruiz, L Lorente-Grandoso, ... Kidney international 94 (2), 363-371, 2018 | 148 | 2018 |
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial HJL Heerspink, J Radhakrishnan, CE Alpers, J Barratt, S Bieler, U Diva, ... The Lancet 401 (10388), 1584-1594, 2023 | 68 | 2023 |
Clinical and genetic features of autosomal dominant Alport syndrome: a cohort study M Furlano, V Martínez, M Pybus, Y Arce, J Crespí, M del Prado Venegas, ... American Journal of Kidney Diseases 78 (4), 560-570. e1, 2021 | 65 | 2021 |
New therapeutic options for Alport syndrome R Torra, M Furlano Nephrology Dialysis Transplantation 34 (8), 1272-1279, 2019 | 63 | 2019 |
Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players A Domingo-Gallego, M Pybus, G Bullich, M Furlano, L Ejarque-Vila, ... Nephrology Dialysis Transplantation 37 (4), 687-696, 2022 | 61 | 2022 |
Autosomal dominant tubulointerstitial kidney disease: clinical presentation of patients with ADTKD-UMOD and ADTKD-MUC1 N Ayasreh, G Bullich, R Miquel, M Furlano, P Ruiz, L Lorente, O Valero, ... American Journal of Kidney Diseases 72 (3), 411-418, 2018 | 61 | 2018 |
Genetic kidney diseases as an underrecognized cause of chronic kidney disease: the key role of international registry reports R Torra, M Furlano, A Ortiz, E Ars Clinical kidney journal 14 (8), 1879-1885, 2021 | 42 | 2021 |
RICORS2040: the need for collaborative research in chronic kidney disease A Ortiz Clinical kidney journal 15 (3), 372-387, 2022 | 40 | 2022 |
Tablas para la estimación del filtrado glomerular mediante la nueva ecuación CKD-EPI a partir de la concentración de creatinina sérica C Canal, R Pellicer, C Facundo, S Gràcia-Garcia, R Montañés-Bermúdez, ... Nefrología (Madrid) 34 (2), 223-229, 2014 | 29 | 2014 |
Clinical uses of 1, 25-dihydroxy-19-nor-vitamin D2 (Paricalcitol) J Bover, I Dasilva, M Furlano, MJ Lloret, MM Diaz-Encarnacion, J Ballarin, ... Current vascular pharmacology 12 (2), 313-323, 2014 | 24 | 2014 |
Autosomal dominant polycystic kidney disease: clinical assessment of rapid progression M Furlano, I Loscos, T Marti, G Bullich, N Ayasreh, A Rius, L Roca, ... American journal of nephrology 48 (4), 308-317, 2018 | 23 | 2018 |
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial BH Rovin, J Barratt, HJL Heerspink, CE Alpers, S Bieler, DW Chae, ... The Lancet 402 (10417), 2077-2090, 2023 | 22 | 2023 |
ADPedKD: a global online platform on the management of children with ADPKD S De Rechter, D Bockenhauer, LM Guay-Woodford, I Liu, AJ Mallett, ... Kidney international reports 4 (9), 1271-1284, 2019 | 22 | 2019 |
Papel del fósforo en la enfermedad renal crónica MJ Lloret, J Bover, I DaSilva, M Furlano, C Ruiz-García, N Ayasreh Nefrología (Suplemento Extraordinario) 4, 2-10, 2013 | 22 | 2013 |
Novel homozygous OSGEP gene pathogenic variants in two unrelated patients with Galloway-Mowat syndrome: case report and review of the literature A Domingo-Gallego, M Furlano, M Pybus, D Barraca, AB Martínez, ... BMC nephrology 20, 1-8, 2019 | 21 | 2019 |
English–Latin nomenclature conundrum: should we use kidneylogy, kidneylogist? J Bover, ML Haarhaus, M Furlano, P Ureña, M Vervloet, V Brandenburg, ... Kidney International 98 (5), 1352-1353, 2020 | 16 | 2020 |
Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation–safety, efficacy, and patient adherence MJ Lloret, C Ruiz-García, I DaSilva, M Furlano, Y Barreiro, J Ballarín, ... Patient preference and adherence, 1147-1156, 2013 | 15 | 2013 |
MYH9 associated nephropathy M Furlano, R Arlandis, M del Prado Venegas, S Novelli, J Crespi, ... Nefrología (English Edition) 39 (2), 133-140, 2019 | 13 | 2019 |